Neoleukin Therapeutics, Inc is a drug manufacturers-specialty & generic business based in the US. Neoleukin Therapeutics shares (NLTX) are listed on the NASDAQ and all prices are listed in US Dollars. Neoleukin Therapeutics employs 78 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Neoleukin Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NLTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Neoleukin Therapeutics stock price (NASDAQ: NLTX)Use our graph to track the performance of NLTX stocks over time.
Neoleukin Therapeutics shares at a glance
|Latest market close||$10.03|
|52-week range||$6.92 - $17.95|
|50-day moving average||$9.14|
|200-day moving average||$11.30|
|Wall St. target price||$20.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.94|
Buy Neoleukin Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Neoleukin Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Neoleukin Therapeutics price performance over time
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||4.48%|
|3 months (2021-05-04)||-11.40%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
Neoleukin Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-16.79%|
|Return on equity TTM||-25.05%|
|Market capitalisation||$296 million|
TTM: trailing 12 months
Shorting Neoleukin Therapeutics shares
There are currently 2.1 million Neoleukin Therapeutics shares held short by investors – that's known as Neoleukin Therapeutics's "short interest". This figure is 0.1% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting Neoleukin Therapeutics shares can be evaluated.
Neoleukin Therapeutics's "short interest ratio" (SIR)
Neoleukin Therapeutics's "short interest ratio" (SIR) is the quantity of Neoleukin Therapeutics shares currently shorted divided by the average quantity of Neoleukin Therapeutics shares traded daily (recently around 207564.91935484). Neoleukin Therapeutics's SIR currently stands at 9.92. In other words for every 100,000 Neoleukin Therapeutics shares traded daily on the market, roughly 9920 shares are currently held short.
However Neoleukin Therapeutics's short interest can also be evaluated against the total number of Neoleukin Therapeutics shares, or, against the total number of tradable Neoleukin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neoleukin Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Neoleukin Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0949% of the tradable shares (for every 100,000 tradable Neoleukin Therapeutics shares, roughly 95 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Neoleukin Therapeutics.
Find out more about how you can short Neoleukin Therapeutics stock.
Neoleukin Therapeutics share dividends
We're not expecting Neoleukin Therapeutics to pay a dividend over the next 12 months.
Neoleukin Therapeutics share price volatility
Over the last 12 months, Neoleukin Therapeutics's shares have ranged in value from as little as $6.92 up to $17.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neoleukin Therapeutics's is 0.9744. This would suggest that Neoleukin Therapeutics's shares are less volatile than average (for this exchange).
Neoleukin Therapeutics overview
Neoleukin Therapeutics, Inc. , a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc.
Stocks similar to Neoleukin Therapeutics
Neoleukin Therapeutics in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Stocks That Hit 52-Week Lows On Tuesday
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Frequently asked questionsWhat percentage of Neoleukin Therapeutics is owned by insiders or institutions?
Currently 22.339% of Neoleukin Therapeutics shares are held by insiders and 68.194% by institutions. How many people work for Neoleukin Therapeutics?
Latest data suggests 78 work at Neoleukin Therapeutics. When does the fiscal year end for Neoleukin Therapeutics?
Neoleukin Therapeutics's fiscal year ends in December. Where is Neoleukin Therapeutics based?
Neoleukin Therapeutics's address is: 1616 Eastlake Avenue East, Seattle, WA, United States, 98102 What is Neoleukin Therapeutics's ISIN number?
Neoleukin Therapeutics's international securities identification number is: US64049K1043 What is Neoleukin Therapeutics's CUSIP number?
Neoleukin Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03842B101
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert